Key points are not available for this paper at this time.
Chronic Lymphocytic Leukemia (CLL) is a complex blood cancer involving genetic changes that lead to the overproduction of abnormal B lymphocytes. Diagnosis involves blood tests and genetic analysis, while treatment options include chemotherapy, immunotherapy, and targeted drug therapy. CLL is most common in older adults, particularly white males, and may progress slowly or aggressively. The disease's severity and survival rates may vary, with newer drug combinations reducing the need for bone marrow transplants. CLL involves immune dysregulation from early stages, where its cells suppress immune function by interacting with and inhibiting T and B cells. They evade the immune system through mechanisms like downregulating HLA-I and expressing inhibitory molecules such as PD-L1. Immunotherapy, including monoclonal antibodies targeting markers like CD20, and CAR-T cell therapy, plays a crucial role in treating CLL, though challenges remain, particularly in T cell functionality. The FDA-approved tyrosine kinase inhibitor ibrutinib is another significant advancement in CLL treatment. This paper covers two ongoing clinical trials in CLL treatment with immunotherapy. The first trial tests Xcellerated T Cells, an engineered autologous T cell product, aiming to enhance the anti-tumor immune response and establish safety and efficacy (NCT00058656). The second trial combines ibrutinib, fludarabine, and pembrolizumab to overcome resistance seen with single-agent therapies, enhancing treatment efficacy in high-risk or relapsed CLL patients (NCT03204188). Both studies focus on improving immune-based treatments for CLL. Immunotherapy offers promising treatment options, especially for resistant cases. However, Challenges such as disease heterogeneity and treatment resistance remain in CLL. Ongoing research focuses on personalized medicine and innovative therapies to improve patient outcomes.
Rice Areepitak (Sun,) studied this question.